Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Mantle-Cell 2Lymphoma, Non-Hodgkin 1Leukemia, B-Cell 1Leukemia 1

Interventions

Rituximab 6venetoclax 5Bendamustine Hydrochloride 5obinutuzumab 3acalabrutinib 3zanubrutinib 2pirtobrutinib 2idelalisib 2ibrutinib 2Chlorambucil 2umbralisib 1ublituximab 1ofatumumab 1fludarabine phosphate 1duvelisib 1atezolizumab 1Pharmacogenomic Testing 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Lymphocytic, Chronic, B-Cell × acalabrutinib × Clear all
NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Acerta Pharma BV

Phase 3 Active not recruiting
310 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02475681 2025-08-27

ElevateTN

Acerta Pharma BV

Phase 3 Active not recruiting
535 enrolled 19 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03836261 2024-12-27

AMPLIFY

Acerta Pharma BV

Phase 3 Active not recruiting
984 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡